Table 2 Methodology and quality of inclined studies
Authors | Year | Research design | Country | Treatment duration /years | Serum drug level (mg/mL) | Bone metabolism index |
|---|---|---|---|---|---|---|
Akin R [11] | 1998 | Retrospective | Turkey | 2.4 ± 0.2 | 66 ± 2.2 | Ca, P, ALP, BMD |
Kafali G [17] | 1999 | Retrospective | Turkey | > 0.5 | – | ALP, BMD |
Erbayat Altay E [14] | 2000 | Retrospective | Turkey | 3.1 + 1.8 (1–6) | – | BMD |
Voudris K [23] | 2002 | Retrospective | Greece | > 0.5 | 59.1 ± 2.7 | ALP |
Caksen H [15] | 2002 | Retrospective | Turkey | 1.93 ± 1.90 | 85.29 ± 11.72 | Ca, P, ALP, PTH, OC |
Oner N [19] | 2004 | Retrospective | Turkey | > 0.5 | 56.8 ± 15.5 | Ca, P, BMD |
Ecevit C [16] | 2004 | Retrospective | Turkey | > 0.5 | 53.75 ± 23.94 | BMD |
Kumandas S [18] | 2006 | Retrospective | Turkey | 2.9 ± 1.2 | 67.37 ± 8.31 | Ca, P, ALP, BMD, PTH, OC, 25-OH-VitD |
Babayigit A [13] | 2006 | Retrospective | Turkey | > 1 | – | Ca, P, ALP, BMD, PTH, 25-OH-VitD |
Rauchenzauner M [21] | 2010 | Retrospective | Austria | > 0.5 | – | Ca, P, 25-OH-VitD |
Aksoy A [12] | 2011 | Retrospective | Turkey | 3.23 ± 1.09 | 56.96 ± 7.34 | Ca, P, ALP, BMD, OC, 25-OH-VitD |
Yaghini O [20] | 2014 | Retrospective | Iran | > 0.5 | – | Ca, P, ALP, BMD, PTH |
Serin HM [22] | 2015 | Retrospective | Turkey | > 0.5 | – | Ca, P, ALP, BMD, PTH |
Hasaneen B [7] | 2017 | Retrospective | Egypt | 1.3 ± 0.6 | – | Ca, P, BMD, PTH |